E14682 Background: Gastric cancer carries a poor prognosis and is one of the leading causes of cancer deaths worldwide. Adjuvant chemotherapy did not result in a survival advantage in Caucasian populations. Thus, other therapeutic options including perioperative chemotherapy were investigated: In the neoadjuvant setting, combinations of epirubicin, cyclophosphamide and fluorouracile or capecitabine as well as cisplatin or oxaliplatin improved outcome versus surgery alone. Here, we report on the use of the EOX regimen in the neoadjuvant setting which had shown a trend in advanced gastric cancer of superior survival outcome. Methods: 20 Patients (median age: 70.5, range 36-85, years; 15 pts > 65 years) with locally advanced adenocarcinoma of the upper GI-tract received 3 courses of perioperative chemotherapy with epirubicin 50 mg/m2, day1, oxaliplatin 130 mg/m2, day 1, and capecitabine 2,000 mg/m2, days 1- 14, of a 3-week cycle. Toxicity was assessed by CTC (Common Toxicity Criteria) for every cycle. Progression free survival (PFS) was defined as interval from surgery to disease progression assessed by PET-CT which was performed at diagnosis and after 3 cycles of chemotherapy and every twelve weeks thereafter. Results: 17 pts completed all three planned cycles of chemotherapy, 2 pts received only one cycle due to rapid tumor progression, 1 patient is currently still on treatment. 11 pts underwent surgery with curative resection with 2 pCRs. 4 pts remained inoperable despite chemotherapy and 3 pts are waiting for surgery. 1 patient died after front-line chemotherapy due to rapid tumor progression. After surgery, 3 pts died after a median of 6.8 (range: 5-8) months. Only 2 pts experienced grade 3-4 toxicities including nausea, diarrhea and hand-foot syndrome and one non-life-threatening pulmonary embolism. Dose reduction of capecitabine to 75% due to toxicity was necessary in 2 pts. PFS was 8.7 month (5.3-12.1 95%CI); overall survival is not reached, yet. Conclusions: We conclude that EOX is a well tolerated, safe, and efficacious as neoadjuvant treatment in elderly patients with locally advanced adenocarcinoma of the upper GI-tract encouraging further investigation.